The clinical outcomes of triple antiplatelet therapy versus dual antiplatelet therapy for high-risk patients after coronary stent implantation: a meta-analysis of 11 clinical trials and 9,553 patients

Zhong-Guo Fan 1,.*, Guo-Bin Ding 1,.*, Xiao-Bo Li 1,2, Xiao-Fei Gao 1,3, Ya-Li Gao 1, and Nai-Liang Tian 1,3

1Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 2Department of Cardiology, Taixing People’s Hospital, Yangzhou University, Taizhou, 3Department of Cardiology, Nanjing Heart Center, Nanjing, People's Republic of China

*These authors contributed equally to this work

Background: The optimal antiplatelet regimen after in-coronary intervention among patients presenting with complex coronary artery lesions or acute coronary syndrome (ACS) has remained unclear. This study sought to evaluate the clinical outcomes of triple antiplatelet treatment (TAPT) (cilostazol added to aspirin plus clopidogrel) in these patients.

Methods: The PubMed, EMBASE, MEDLINE, and other Internet sources were searched for relevant articles. The primary end point was major adverse cardiac events (MACE), including all-cause mortality, myocardial infarction, and target vessel revascularization. The incidence of definite/probable stent thrombosis and bleeding were analyzed as the safety end points.

Results: Eleven clinical trials involving 9,553 patients were analyzed. The risk of MACE was significantly decreased following TAPT after stent implantation in the ACS subgroup (odds ratio [OR]: 0.72; 95% confidence interval [CI]: 0.61–0.85; P<0.001), which might mainly result from the lower risk of all-cause mortality in this subset (OR: 0.62; 95% CI: 0.48–0.80; P<0.001). The risk of bleeding was not increased with respect to TAPT.

Conclusion: TAPT after stent implantation was associated with feasible benefits on reducing the risk of MACE, especially on reducing the incidence of all-cause mortality among patients suffering from ACS, without higher incidence of bleeding. Larger and more powerful randomized trials are still warranted to prove the superiority of TAPT for such patients.

Keywords: triple antiplatelet treatment, dual antiplatelet treatment, stent implantation, complex lesions, acute coronary syndrome

Introduction

Since the application of the rapidly developed interventional techniques widely in the clinic, improved clinical outcomes have been reported among patients with coronary artery disease (CAD), especially those suffering from acute coronary syndrome (ACS) or presenting with complex coronary artery lesions. 1 Though successful stenting is considered to strengthen these beneficial effects, the risk of stent thrombosis (ST) and restenosis among these patients is still high, which are considered frequent causes of death and recurrent myocardial infarction (MI) derived from the superimposition of a platelet-rich thrombus. 2 As a result, a routine dual antiplatelet treatment (DAPT) consisting of aspirin and a P2Y12 receptor antagonist has been chosen as an adjuvant therapy after percutaneous coronary intervention (PCI). 3 However, ~10% of patients...
undergoing stent implantation receiving DAPT developed thrombotic events leading to high morbidity and mortality, which were thought to be driven by high on-treatment platelet reactivity (HTPR). Currently, overcoming HTPR and optimizing the antiplatelet regimen post-PCI for these patients still remain as important problems.

Cilostazol is a selective inhibitor of phosphodiesterase III, which inhibits platelet aggregation in response to ADP, epinephrine, collagen, and arachidonic acid. It can also suppress the production of platelet-derived endothelial cell growth factor, which is considered to drive its extensive application in patients undergoing stent implantation.

In recent years, several large observational clinical trials (Obss) and meta-analyses have demonstrated that adding cilostazol to aspirin plus clopidogrel decreased the risk of major adverse cardiac events (MACE) compared to the conventional dual regimen. A recent meta-analysis published by Bundhun et al as well as several other randomized trials, stated the superiority of triple antiplatelet therapy (TAPT) for type 2 diabetes mellitus (T2DM) patients after intracoronary stenting procedure. The large randomized controlled trial (RCT) conducted by Lee et al indicated lower risk of late luminal loss, percentage intimal hyperplasia volume, and angiographic restenosis related to the TAPT, resulting in decreased risk of target lesion revascularization (TLR) after 12-month follow-up. However, the Coronary Bifurcation Stent (COBIS) II Registry, focused on patients with bifurcation lesions, showed that TAPT post-PCI had no beneficial effects on reducing the risk of long-term clinical outcomes, and another clinical trial showed similar negative results of TAPT among patients suffering from unprotected left main (LM) disease. Of note, patients suffering from ACS or with complex coronary artery lesions are highly likely to develop thrombotic events after stent implantation. These conflicting data have called the optimal antiplatelet regimen into question, and there is no related meta-analysis paying attention to this topic. Therefore, we performed this meta-analysis involving as many related clinical trials as possible to evaluate the efficacy and safety of TAPT compared to DAPT after stent implantation for patients suffering from ACS or with complex coronary artery lesions.

**Methods**

**Literature search**

The references comparing clinical outcomes of TAPT with DAPT post-PCI among patients presenting with complex coronary artery lesions (defined as long coronary artery lesions, chronic total occlusion lesions, unprotected LM lesions, bifurcation lesions, multivessel artery disease, or the composite of all these) and/or suffering from ACS were searched in the PubMed, EMBASE, MEDLINE, and the Cochrane Controlled Trials Registry from their dates of inception until June 2016, as well as several other Internet sources. Combinations of several relevant keywords were used to make sure all relevant studies were included, including “triple antiplatelet therapy”, “TAPT”, “dual antiplatelet therapy”, “DAPT”, “acute myocardial infarction or AMI”, “acute coronary syndrome or ACS”, “chronic total occlusion”, “left main”, “bifurcation”, “long lesions”, “stent implantation”, “percutaneous coronary intervention” or “PCI”. All potentially relevant citations and references from published reviews or meta-analyses were subsequently screened for eligibility.

**Inclusion and exclusion criteria**

The included studies were required to fulfill the following criteria: 1) adult patients with complex coronary artery lesions and/or suffering from ACS (age range: 18–90 years) undergoing stent implantation; 2) clinical trials comparing the TAPT and the DAPT groups; and 3) reported results of adverse clinical events. The exclusion criteria were as follows: 1) patients with cardiogenic shock; 2) nonhuman or ongoing studies; 3) non-English-language studies; 4) reviews or meta-analyses; and 5) duplicated studies, or different studies using the same sample.

**Data extraction, synthesis, and quality assessment**

All relevant articles were reviewed by two independent investigators (FZG and DGB) using standardized data abstraction forms to assess their eligibility. The third investigator (LXB) resolved disagreements. These following data were extracted from each included study: the name or the first author of the trial, publication year, baseline demographics, characteristics of lesions, details of antiplatelet regimens and PCI procedure, as well as clinical outcomes during follow-up. These included trials were divided into two subgroups, described as the “complex lesions” subgroup and the “ACS” subgroup. The quality of all retrieved studies was assessed according to the Newcastle–Ottawa Scale (NOS) and the Jadad score for the cohorts and randomized studies, respectively.

**Study end points**

The primary end point of this study was incidence of MACE, including all-cause mortality, MI (including both Q-wave MI and non-Q-wave MI) and target vessel revascularization (TVR) (TLR was used instead in one trial due to the absence of relevant data). The secondary end point was the
risk of stroke. The incidence of definite/probable ST, according to the definition of the Academic Research Consortium,\textsuperscript{21} and bleeding, including major and minor bleeding, were chosen to be evaluated as the safety end points. There were slight differences among these included trials in terms of the definitions of clinical end points, and standardized definitions were followed.

Statistical analysis
This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.\textsuperscript{22} STATA 12.0 (StataCorp LP, College Station, TX, USA) was used to perform the statistical analysis. All the end points were applied as dichotomous variables, expressed with odds ratios (ORs) and 95% confidence intervals (CIs). When a $P$-value was less than 0.05, it was considered statistically significant. The Cochran’s $Q$ test and the $F$ statistic were used to measure statistical heterogeneity. Significant heterogeneity was considered and a random-effects model would be selected if the $P$-value of the $Q$ test was $<0.10$ and/or the $F$ was $\geq 50\%$. In contrast, the fixed-effects model with the Mantel–Haenszel method was used instead. Publication bias was examined via the Egger’s test ($P$, 0.1 for significant asymmetry).\textsuperscript{23} The sensitivity analyses were also performed by excluding one study at a time to assess the stability of the overall treatment effects. All of the $P$-values were two tailed.

Results

Eligible studies and patient characteristics
After screening 996 initial articles through the electronic databases and another 54 articles from several other Internet sources, 11 clinical trials were finally identified, including 7 RCTs\textsuperscript{16,24–29} and 4 Obs\textsuperscript{9,10,17,18} (Figure 1). Among these included clinical trials, there were 2 trials for long artery lesions,\textsuperscript{16,24} 1 for unprotected LM disease,\textsuperscript{18} 1 for bifurcation lesion,\textsuperscript{17} and 1 for mixed complex lesions.\textsuperscript{29} Another 6 clinical trials focused on patients suffering from ACS\textsuperscript{9,10,25–28} Only 1 observational trial\textsuperscript{17} performed subanalysis following propensity score matching, and the data were analyzed from the matched subgroup instead. The baseline characteristics, antiplatelet regimens and procedural details of the included studies are summarized in Tables 1–3. The qualities of included studies are described in Table 3.

Major adverse cardiac events
As shown in Figure 2, the overall risk of MACE was not reduced significantly following TAPT (OR: 0.80; 95%
### Table 1: Baseline characteristics of the included trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>TAPT regimen</th>
<th>DAPT regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>DECLARE-LONG trial(^{14})</td>
<td>RCT</td>
<td>Loading: aspirin 200 mg, clopidogrel 300 mg, cilostazol 200 mg; maintenance: aspirin 200 mg/d, clopidogrel 75 mg/d, cilostazol 100 mg twice daily; (\geq 6) m</td>
<td>Loading: aspirin 200 mg, clopidogrel 300 mg; maintenance: aspirin 200 mg/d, clopidogrel 75 mg/d; (\geq 6) m</td>
</tr>
<tr>
<td>DECLARE-LONG II trial(^{16})</td>
<td>RCT</td>
<td>Loading: aspirin 200 mg, clopidogrel 300 mg, cilostazol 200 mg; maintenance: aspirin 200 mg/d, clopidogrel 75 mg/d, (\geq 12) m; cilostazol 100 mg twice daily, for 8 m</td>
<td>Loading: aspirin 200 mg, clopidogrel 300 mg; maintenance: aspirin 200 mg/d, clopidogrel 75 mg/d; (\geq 12) m</td>
</tr>
<tr>
<td>Lee et al(^{20})</td>
<td>Obs</td>
<td>DAPT + cilostazol, (\geq 3) m</td>
<td>Aspirin + clopidogrel or ticlopidine</td>
</tr>
<tr>
<td>“COBIS II Registry”(^{23})</td>
<td>Obs</td>
<td>Loading: aspirin 300 mg, clopidogrel 300–600 mg, cilostazol 200 mg; maintenance: aspirin indefinitely, clopidogrel 75 mg/d, (\geq 6) m; + cilostazol</td>
<td>Loading: aspirin 300 mg, clopidogrel 300–600 mg; maintenance: aspirin indefinitely, clopidogrel 75 mg/d; (\geq 6) m</td>
</tr>
<tr>
<td>Yoon et al(^{29})</td>
<td>RCT</td>
<td>Loading: aspirin 300 mg, clopidogrel 300 mg, cilostazol 200 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, for (12) m; cilostazol 100 mg twice daily, for 3 m</td>
<td>Loading: aspirin 300 mg, clopidogrel 300–600 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, for (12) m</td>
</tr>
<tr>
<td>Kim et al(^{25})</td>
<td>RCT</td>
<td>Loading: aspirin 300 mg, clopidogrel 600 mg, cilostazol 400 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d; + cilostazol 200 mg, for (1) m</td>
<td>Loading: aspirin 300 mg, clopidogrel 300–600 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, for (1) m</td>
</tr>
<tr>
<td>Chen et al(^{10})</td>
<td>Obs</td>
<td>Loading: aspirin 200 mg, clopidogrel 300–600 mg, cilostazol 200 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, (\geq 6) m; cilostazol 100 mg twice daily, (\geq 1) m</td>
<td>Loading: aspirin 300 mg, clopidogrel 300–600 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, (\geq 6) m</td>
</tr>
<tr>
<td>Han et al(^{27})</td>
<td>RCT</td>
<td>Aspirin 300 mg/d for (1) m, followed by 100 mg/d indefinitely; clopidogrel 300–600 mg, followed by 75 mg/d, for (3–12) m; + cilostazol 100 mg twice daily, for 6 m</td>
<td>Aspirin 300 mg/d for (1) m, followed by 100 mg/d indefinitely; clopidogrel 300–600 mg, followed by 75 mg/d, for (3–6) m</td>
</tr>
<tr>
<td>Ahn et al(^{28})</td>
<td>RCT</td>
<td>Loading: aspirin 200 mg, clopidogrel 300 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, for (24) m; cilostazol 100 mg twice daily</td>
<td>Loading: aspirin 200 mg, clopidogrel 300 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, for (24) m</td>
</tr>
<tr>
<td>Jeong et al(^{26})</td>
<td>RCT</td>
<td>Loading: aspirin 300 mg, clopidogrel 600 mg; maintenance: aspirin 200 mg/d, clopidogrel 75 mg/d, for (1) m; cilostazol 100 mg twice daily, for (1) m</td>
<td>Loading: aspirin 300 mg, clopidogrel 600 mg; maintenance: aspirin 200 mg/d, clopidogrel 75 mg/d, for (1) m</td>
</tr>
<tr>
<td>Lee et al(^{9})</td>
<td>Obs</td>
<td>Loading: aspirin 300 mg, clopidogrel 450–600 mg, cilostazol 200 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, (\geq 6) m; cilostazol 100 mg twice daily, (\geq 1) m</td>
<td>Loading: aspirin 300 mg, clopidogrel 450–600 mg; maintenance: aspirin 100 mg/d, clopidogrel 75 mg/d, (\geq 6) m</td>
</tr>
</tbody>
</table>

**Note:** *Subgroup following propensity score matching.

**Abbreviations:** COBIS, COronary Bifurcation Stent; d, day; DAPT, dual antiplatelet therapy; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; m, month; Obs, observational trials; RCT, randomized controlled trials; TAPT, triple antiplatelet therapy.

### Table 2: Characteristics of the patients’ past medical histories among the included trials

<table>
<thead>
<tr>
<th>Study</th>
<th>TAPT/DAPT</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients, n</td>
<td>Age, y</td>
</tr>
<tr>
<td>DECLARE-LONG trial(^{14})</td>
<td>250/250</td>
<td>60.9/61.2</td>
</tr>
<tr>
<td>DECLARE-LONG II trial(^{16})</td>
<td>250/249</td>
<td>60.9/62.1</td>
</tr>
<tr>
<td>Lee et al(^{9})</td>
<td>124/121</td>
<td>63.8/64.9</td>
</tr>
<tr>
<td>“COBIS II Registry”(^{23})</td>
<td>651/651</td>
<td>61.9/62.0</td>
</tr>
<tr>
<td>Yoon et al(^{29})</td>
<td>308/307</td>
<td>65.0/64.2</td>
</tr>
<tr>
<td>Kim et al(^{25})</td>
<td>30/30</td>
<td>62.3/63.9</td>
</tr>
<tr>
<td>Chen et al(^{10})</td>
<td>1,634/2,569</td>
<td>62.0/62.0</td>
</tr>
<tr>
<td>Han et al(^{27})</td>
<td>604/608</td>
<td>59.6/60.2</td>
</tr>
<tr>
<td>Ahn et al(^{28})</td>
<td>64/66</td>
<td>62.1/65.2</td>
</tr>
<tr>
<td>Jeong et al(^{26})</td>
<td>30/30</td>
<td>61.3/64.0</td>
</tr>
<tr>
<td>Lee et al(^{9})</td>
<td>195/532</td>
<td>69/72</td>
</tr>
</tbody>
</table>

**Note:** *Subgroup following propensity score matching.

**Abbreviations:** COBIS, COronary Bifurcation Stent; DAPT, dual antiplatelet therapy; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; NA, not available; TAPT, triple antiplatelet therapy; y, years.
Table 3  Angiographic and procedural characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>LM, n</th>
<th>LAD, n</th>
<th>LCX, n</th>
<th>RCA, n</th>
<th>Stent length, mm</th>
<th>Stent number, n</th>
<th>Stent diameter, mm</th>
<th>Study quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>DECLARE-LONG trial*</td>
<td>0/0</td>
<td>155/152</td>
<td>23/29</td>
<td>72/69</td>
<td>41.4/40.3</td>
<td>1.49/1.47</td>
<td>NA</td>
<td>2</td>
</tr>
<tr>
<td>DECLARE-LONG II trial*</td>
<td>0/0</td>
<td>149/155</td>
<td>40/29</td>
<td>61/65</td>
<td>37.3/39.1</td>
<td>1.5/1.6</td>
<td>NA</td>
<td>5</td>
</tr>
<tr>
<td>Lee et al*</td>
<td>124/121</td>
<td>NA</td>
<td>NA</td>
<td>50/51</td>
<td>42.6/33.9</td>
<td>2.0/1.6</td>
<td>3.5/3.47</td>
<td>9*</td>
</tr>
<tr>
<td>“COBIS II Registry”</td>
<td>212/267</td>
<td>300/287</td>
<td>55/76</td>
<td>24/21</td>
<td>DES</td>
<td>2.0/2.0</td>
<td>NA</td>
<td>8*</td>
</tr>
<tr>
<td>Youn et al*</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>50/51</td>
<td>51.1/49.7</td>
<td>2.3/2.2</td>
<td>3.0/3.05</td>
<td>3</td>
</tr>
<tr>
<td>Kim et al*</td>
<td>0/0</td>
<td>12/16</td>
<td>3/6</td>
<td>15/8</td>
<td>DES</td>
<td>NA</td>
<td>NA</td>
<td>2</td>
</tr>
<tr>
<td>Chen et al*</td>
<td>23/21</td>
<td>866/1,387</td>
<td>169/242</td>
<td>576/919</td>
<td>DES</td>
<td>25.7/25.3</td>
<td>1.5/1.35</td>
<td>8*</td>
</tr>
<tr>
<td>Han et al*</td>
<td>16/14</td>
<td>489/485</td>
<td>155/146</td>
<td>333/335</td>
<td>DES/BSM</td>
<td>37.9/38.8</td>
<td>1.58/1.56</td>
<td>3</td>
</tr>
<tr>
<td>Ahn et al*</td>
<td>0/0</td>
<td>44/40</td>
<td>10/14</td>
<td>10/12</td>
<td>DES</td>
<td>24.5/25.0</td>
<td>2.38/2.36</td>
<td>2</td>
</tr>
<tr>
<td>Jeong et al*</td>
<td>0/0</td>
<td>12/10</td>
<td>12/9</td>
<td>6/11</td>
<td>DES</td>
<td>33/31</td>
<td>1.4/1.3</td>
<td>3</td>
</tr>
<tr>
<td>Lee et al*</td>
<td>2/14</td>
<td>100/248</td>
<td>26/77</td>
<td>66/188</td>
<td>NA</td>
<td>26.0/26.1</td>
<td>1.6/1.4</td>
<td>8*</td>
</tr>
</tbody>
</table>

Notes: *The qualities of observational trials were assessed by the Newcastle–Ottawa Scale, and the maximum score =9. The qualities of included randomized trials were assessed by the Jadad score. *Subgroup following propensity score matching.

Abbreviations: BMS, bare mental stents; COBIS, Coronary Bifurcation Stent; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; DES, drug-eluting stent; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main coronary artery; RCA, right coronary artery; NA, not available.

---

**Figure 2**  The ORs of MACE associated with TAPT compared with DAPT.

Notes: Forest plots of the efficacy and safety end points of the included trials. Weights are from random-effects analysis. *Subgroup following propensity score matching.

Abbreviations: ACS, acute coronary syndrome; AMI, acute myocardial infarction; CI, confidence interval; COBIS, Coronary Bifurcation Stent; DAPT, dual antiplatelet treatment; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; MACE, major adverse cardiac event; OR, odds ratio; TAPT, triple antiplatelet treatment.
CI: 0.62–1.02, \( P=0.077; F=58.9\%, P=0.013 \); a similar result was observed in the subgroup of complex lesions (OR: 0.89, 95% CI: 0.57–1.37, \( P=0.588; F=64.3\%, P=0.024 \)), while the contrary result was shown in the ACS subgroup (OR: 0.72, 95% CI: 0.61–0.85, \( P<0.001; F=0\%, P=0.407 \)). The results from the Egger’s test indicated no publication bias (\( P=0.918 \)), and the stability of results was proved by the sensitivity analysis.

### All-cause mortality

As depicted in Figure 3, lower overall risk of all-cause mortality was observed related to TAPT (OR: 0.75, 95% CI: 0.61–0.92, \( P=0.006; F=38\%, P=0.115 \)), which were mainly derived from the results of the ACS subgroup (OR: 0.62, 95% CI: 0.48–0.80, \( P<0.001; F=0\%, P=0.996 \)). No publication bias was found by the Egger’s test (\( P=0.250 \)). The sensitivity analysis demonstrated these superior effects of TAPT.

### Myocardial infarction

There was no difference between the TAPT group and the DAPT group with respect to the incidence of MI (OR: 0.97, 95% CI: 0.63–1.51, \( P=0.901; F=0\%, P=0.989 \), Figure 4), as well as the ACS (OR: 0.87, 95% CI: 0.43–1.79, \( P=0.710; F=0\%, P=0.730 \)) and complex lesions subgroups (OR: 1.04, 95% CI: 0.60–1.81, \( P=0.894; F=0\%, P=1.000 \). No publication bias was encountered via the Egger’s test (\( P=0.219 \)).

### Target vessel revascularization

The incidence of TVR did not differ significantly between the two groups (OR: 0.72, 95% CI: 0.61–0.85, \( P=0.006; F=0\%, P=0.115 \)), and similar results could also

<table>
<thead>
<tr>
<th>Study ID</th>
<th>All-cause mortality</th>
<th>OR (95% CI)</th>
<th>% weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complex lesions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DECLARE-LONG trial(^a)</td>
<td></td>
<td>0.20 (0.01, 4.15)</td>
<td>1.17</td>
</tr>
<tr>
<td>DECLARE-LONG II trial(^b)</td>
<td></td>
<td>2.02 (0.50, 8.15)</td>
<td>1.38</td>
</tr>
<tr>
<td>Lee et al(^p)</td>
<td></td>
<td>1.46 (0.60, 3.55)</td>
<td>3.83</td>
</tr>
<tr>
<td>“COBIS II Registry”(^m)</td>
<td></td>
<td>0.93 (0.55, 1.58)</td>
<td>13.47</td>
</tr>
<tr>
<td>Youn et al(^p)</td>
<td></td>
<td>3.40 (0.93, 12.48)</td>
<td>1.36</td>
</tr>
<tr>
<td>Subtotal (( I^2=26.2%, P=0.247 ))</td>
<td></td>
<td>1.21 (0.82, 1.80)</td>
<td>21.21</td>
</tr>
<tr>
<td>ACS or AMI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chen et al(^o)</td>
<td></td>
<td>0.63 (0.45, 0.88)</td>
<td>44.19</td>
</tr>
<tr>
<td>Han et al(^p)</td>
<td></td>
<td>0.63 (0.34, 1.20)</td>
<td>11.38</td>
</tr>
<tr>
<td>Ahn et al(^m)</td>
<td></td>
<td>0.51 (0.04, 5.74)</td>
<td>0.91</td>
</tr>
<tr>
<td>Lee et al(^p)</td>
<td></td>
<td>0.60 (0.37, 0.97)</td>
<td>22.30</td>
</tr>
<tr>
<td>Kim et al(^p)</td>
<td>(Excluded)</td>
<td>0.00</td>
<td></td>
</tr>
<tr>
<td>Jeong et al(^m)</td>
<td>(Excluded)</td>
<td>0.00</td>
<td></td>
</tr>
<tr>
<td>Subtotal (( I^2=0.0%, P=0.996 ))</td>
<td></td>
<td>0.62 (0.48, 0.80)</td>
<td>78.79</td>
</tr>
<tr>
<td>Overall (( I^2=38.0%, P=0.115 ))</td>
<td></td>
<td>0.75 (0.61, 0.92)</td>
<td>100</td>
</tr>
</tbody>
</table>

Figure 3 The ORs of all-cause mortality associated with TAPT compared with DAPT.

**Notes:** Forest plots of the efficacy and safety end points of the included trials. \(^a\)Subgroup following propensity score matching.

**Abbreviations:** ACS, acute coronary syndrome; AMI, acute myocardial infarction; CI, confidence interval; COBIS, CO-ronary Bifurcation Stent; DAPT, dual antiplatelet treatment; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; OR, odds ratio; TAPT, triple antiplatelet treatment.
be obtained in both subgroups (complex lesions: OR: 0.81, 95% CI: 0.46–1.41, \( P = 0.450; I^2 = 66.6\%, P = 0.017\); ACS: OR: 0.95, 95% CI: 0.65–1.40, \( P = 0.802; I^2 = 33.2\%, P = 0.213\)). Egger’s test indicated that there was no publication bias (\( P = 0.348\)).

### Stroke

TAPT was not associated with lower risk of stroke compared to DAPT (OR: 0.63, 95% CI: 0.32–1.21, \( P = 0.163; I^2 = 0\%\), \( P = 0.790\), Figure 6). In the ACS or the complex lesions subgroup, the incidence of stroke did not differ significantly between the triple treatment and the dual treatment groups (complex lesions: OR: 0.89, 95% CI: 0.36–2.21, \( P = 0.807; I^2 = 0\%\), \( P = 0.681\); ACS: OR: 0.43, 95% CI: 0.16–1.16, \( P = 0.094; I^2 = 0\%\), \( P = 0.798\)). The results from the Egger’s test suggested no publication bias regarding the incidence of stroke (\( P = 0.762\)).

### Safety end points

#### Definite/probable ST

The comparison between TAPT and DAPT showed no significant difference with respect to the risk of definite/probable ST (OR: 1.70, 95% CI: 0.85–3.38, \( P = 0.133; I^2 = 0\%\), \( P = 0.843\), Figure 7), while similar results were observed in the ACS subgroup (OR: 0.67, 95% CI: 0.11–4.02, \( P = 0.661\)) and complex lesions subgroup (OR: 2.00, 95% CI: 0.94–4.30, \( P = 0.074; I^2 = 0\%\), \( P = 0.926\)). No publication bias was observed based on the results of the Egger’s test (\( P = 0.792\)).

#### Bleeding

The incidence of major or minor bleeding was not increased with TAPT compared with DAPT (major bleeding: OR: 1.07, 95% CI: 0.60–1.90, \( P = 0.809; I^2 = 0\%\), \( P = 0.637\), Figure 8; minor bleeding: OR: 1.12, 95% CI: 0.68–1.86,
P=0.649; I^2=0%, P=0.929, Figure 9). No publication bias was observed (P=0.675 and P=0.727 for major and minor bleeding, respectively).

**Discussion**

In this meta-analysis, the major finding was that TAPT after stent implantation seemed to be associated with lower incidence of MACE, compared to DAPT, among ACS patients, which was thought mainly to result from the significant reduction in risk of all-cause mortality in this specific subset. The risk of bleeding, including major and minor bleeding, was not increased after TAPT, and the triple regimen did not reduce the incidence of MI, TVR, ST, and stroke.

The optimal antiplatelet regimen after intracoronary intervention among patients suffering from CAD has remained controversial. The routine dual regimen is used widely for these patients, particularly for patients with conditions complicated with diabetes mellitus (DM), complex coronary artery lesions, and ACS, in whom high risk of developing thrombotic events after stent implantation has been found. After treatment with the conventional dual antiplatelet regimen after stenting procedure, ~10% of patients still developed thrombotic events and subsequently faced higher incidence of adverse events.4,5 Instead, a triple regimen adding cilostazol to the routine DAPT for these patients was considered to obtain better outcomes. Recently, two large RCTs published by Lee et al16 and Han et al27 indicated ideal results of the triple regimen. In the Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions (DECLARE-LONG II) trial,16 499 patients undergoing long stent implantation (stent length: ≥30 mm) were enrolled, and decreased extent of late luminal loss, resulting in reduced risk of 12-month TLR, was observed. Moreover, Han et al27 demonstrated that TAPT
Bundhun et al recently performed a meta-analysis involving patients with complications of CAD and DM undergoing stent implantation; significant reduced risk of MACE was found in the triple group without any increase in risk of bleeding, the results being in line with the mentioned RCTs. However, several other clinical trials showed contrary results. The COBIS II Registry performed a subgroup analysis after propensity score matching, in which 1,302 patients with bifurcation lesions were divided into two groups at a 1:1 ratio and repeatedly analyzed. The final results showed that TAPT had no beneficial effect in terms of improving long-term clinical outcomes, similar to the results from another clinical trial. In the retrospective cohort, a total of 245 patients (124 for TAPT, 121 for DAPT) presenting with unprotected LM disease were enrolled, and only limited or even no benefits of triple regimen were shown in terms of reducing risk of MACE, including death, MI, TVR, or stroke. The conflicting data from these clinical trials indicated that the superiority of TAPT compared to DAPT post-PCI still remains controversial and that there are only specific patient populations that might truly benefit from the regimen.

In this meta-analysis, lower incidence of MACE was observed in the subset of ACS, which might mainly be due to the significant reduced risk of all-cause mortality in this subgroup. To our knowledge, the acute phase of ACS was commonly complicated by the prothrombotic and inflammatory environment, which might aggravate myocardial injury and delay myocardial recovery, leading to worse clinical outcomes although early revascularization had been performed. Furthermore, these negative reactions might also be enhanced by the primary PCI if the procedure lasted a
very long time or if multiple stents were implanted during the primary procedure. It should be noted that the routine dual regimen (aspirin plus a P2Y12 receptor antagonist) post-PCI could only have limited effects in terms of preventing these negative reactions if the patients had HTPR. The new triple regimen of adding cilostazol to aspirin plus clopidogrel for antiplatelet therapy is considered to be helpful. Cilostazol is a selective inhibitor of phosphodiesterase III, which is known to hydrolyze cyclic adenosine monophosphate (cAMP), resulting in the accumulation of cAMP in vascular smooth muscle cells (VSMCs), which can suppress platelet aggregation, thus differing from aspirin or clopidogrel in the antiplatelet mechanism. It might be more helpful in diminishing the prothrombotic and inflammatory response because cilostazol has additional effects in terms of suppressing platelet aggregation. The combination of the three agents might decrease HTPR and lead to intensified antiplatelet effect, which could reduce subsequent damage to myocardial cells and improve myocardial recovery, leading to better clinical outcomes.

Additionally, results from this meta-analysis showed that TAPT had no positive effects in terms of reducing the incidence of TVR, which are contrary to the results obtained by several other meta-analyses. Lee et al had reported that TAPT played a positive role in reducing the risk of TLR among 499 patients undergoing long stent implantation. In their opinion, the possible reasons might be that cilostazol-induced cAMP accumulation inhibits the activation of mitogen-activated protein kinase while upregulating the antioncogenes p53 and p21, leading to induced apoptosis in VSMCs and resulting in the antiproliferative effects on VSMCs. On the other hand, P-selectin-mediated platelet activation and subsequent Mac-1-mediated leukocyte activation are considered to be related with late lumen loss after coronary stenting, while cilostazol plays an important role in inhibiting their expression. However, several other
clinical trials showed that TAPT was not associated with lower risk of TVR and/or TLR compared to DAPT. Though Han et al27 had indicated that TAPT reduced cardiac and cerebral events after 12-month follow-up for patients with ACS, the results of TVR between TAPT group and DAPT group did not show statistical significance (7.8% vs 10.4%, \( P = 0.118 \)). Three other clinical trials17,18,29 among patients presenting with bifurcation lesion, unprotected LM disease or mixed complex lesions, respectively, also provided similar results. It should be noted that underexpansion and malapposition of implanted stents is potentially considered to be related to the development of thrombotic events, which might mainly contribute to most of the adverse events. Among these CAD patients undergoing stent implantation, there are still several difficulties in achieving optimal stent deployment, particularly in those with complex coronary artery lesions or those suffering from ACS. Of note, long or multiple stents implanted during the procedure at one time among these high-risk patients might make it much more difficult to achieve optimal stent deployment. Moreover, the implanted stents with different structures and drug coatings could affect the process of endothelialization, which is thought to be highly responsible for restenosis in stents. Moreover, the PCI procedure with long or multiple stents for these high-risk patients might cause large stress, which could easily induce severe inflammatory response, just as described earlier, affecting the proliferation of VSMCs and leading these patients out of the effects of adding cilostazol to the routine dual regimen. In fact, the follow-up triple regimens, including duration and dosage of the cilostazol added to the routine dual regimen, might also play an important role in the final results. In addition, risk factors, such as more number of current smokers, high incidence of DM, or poor compliance with antiplatelet treatment, occurring in different subsets might also be the possible confounding sources affecting the final results. As a result, these reasons

### Figure 8

The ORs of major bleeding associated with TAPT compared with DAPT.

**Note:** Forest plots of the efficacy and safety end points of the included trials.

**Abbreviations:** CI, confidence interval; COBIS, COronary BIfurcation Stent; DAPT, dual antiplatelet treatment; DECLARE-LONG II, drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions; OR, odds ratio; TAPT, triple antiplatelet treatment.
might explain why the triple regimen did not reduce the risk of MACE, including MI, all-cause mortality or stroke, in the subgroup “complex lesions”.

Several problems remain unsolved in this study. First, it was a dilemma to specify the optimal duration and dosage of cilostazol to be added to the routine dual regimen due to the lack of enough available data. Second, the selection of different types of implanted stents, which play an important role with respect to benefits of TAPT, remained uncertain. As a result, more powerful RCTs focusing on the related topics might be warranted to guide clinical decision making.

Limitations
This study had several limitations. First, this meta-analysis was performed with no individual patient data, and the small sample sizes of the several included RCTs also made the evaluation of efficacy for TAPT easily be influenced. Second, details related to the PCI procedure, such as the time of procedure, types of stents, techniques, and the choices of sheath with different sizes, might be the unavoidable potential confounding factors that influence the medicine’s effects on patients with complex coronary artery lesions. Third, the insufficient analyses of these data from quantitative coronary analysis among each included trial limited us from studying the specific benefits on angiographic results. Fourth, the absence of data with respect to new-generation ADP receptor antagonists, such as prasugrel and ticagrelor, did not allow us to evaluate their safety and efficacy for these included patients. Additionally, adverse reactions to drug reduced tolerance-inducing discontinuation of cilostazol, which might also influence the final results. Last but not the least, there were no strict durations and dosages of TAPT and DAPT for these included patients, and no limited follow-up period for these included trials might also sway the final results.

Conclusion
TAPT post-PCI was seemed to be related with lower risk of MACE, especially in reducing the incidence of all-cause mortality or stroke.
mortality among patients suffering from ACS, without any increased risk of bleeding. However, more powerful randomized clinical trials comparing TAPT to DAPT after PCI procedure in such patients with more precise subgroups are still warranted to guide clinical application of this triple antiplatelet regimen.

Acknowledgment
The study was supported by the Jiangsu Provincial Special Program of Medical Science (BL2013001).

Author contributions
FZG and DGB were involved in the design, literature search, assessment of study quality and drafting of the manuscript. Disagreements were resolved by LXB. FZG and DGB performed statistical analysis and critically revised the manuscript. GXF and GYL constructed the maps. TNL critically revised the original study design and the manuscript. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References